Hemostemix Insider Trading

Hemostemix is a clinical stage biotechnology company based in Calgary, Canada. The company develops, manufactures, and commercializes stem cell therapies derived from blood, targeting a range of medical conditions. Its primary product, ACP-01, has completed a Phase II clinical trial and is being developed for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. In addition to its lead product, Hemostemix is developing a second therapy called NCP-01, which is currently in preclinical trials. NCP-01 is being evaluated for its potential effect on neuropathic pain and motor function recovery. The company operates within the healthcare sector, specifically in the biotechnology industry. Its work centers on advancing blood-derived stem cell treatments through clinical and preclinical research stages with the goal of eventual commercialization. Hemostemix conducts its operations in Canada.